GlassScriptPhysician profile
Danielle L Kamine
NPI 1780983916
$3,220.64
in general payments reported to CMS, 2019-2025
17 companies · $1,143 in 2025
The $1,143 reported for 2025 was more than what 83% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $80.45 · 2022: $608 · 2023: $450 · 2024: $939 · 2025: $1,143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,531.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $577.37 | 2022-2025 | Invega Sustenna, Spravato |
| Supernus Pharmaceuticals, INC. | $565.18 | 2022-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $432.21 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $375.87 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $295.62 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $184.18 | 2021-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $163.40 | 2022-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $157.41 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $123.13 | 2022-2025 | Ingrezza |
| Lundbeck LLC | $97.48 | 2023-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $72.61 | 2022-2025 | Uzedy, Austedo |
| E.R. Squibb & Sons, L.L.C. | $59.88 | 2025 | Cobenfy |
| Lilly USA, LLC | $33.82 | 2025 | Zepbound, Mounjaro |
| Actelion Pharmaceuticals US, INC. | $30.37 | 2025 | Opsynvi, Uptravi |
| Daiichi Sankyo INC. | $28.50 | 2025 | Injectafer |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $11.88 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Kamine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.